peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
BPC-157 appears to promote repair through multiple interconnected pathways, most notably angiogenesis, growth factor signaling, and anti-inflammatory effects
S.MattssonR.et al (2007)
doi: 10.1016/s0021-9673(02)01536-4
Glutathione SepFast MAG is a magnetic version that can be processed in aid of a magnet
[77], whereas in sorghum with simultaneous treatment of jasmonic acid (JA) and humic acid boosted APX activity, resultant in salt tolerance revealed by Ali et al
